Dr Kola Tytler MBBS CertHE MBA MRCGPClinical Lead • iatroX
For patients undergoing long-term glucocorticoid replacement therapy for Addison's disease, routine monitoring includes:
- Blood pressure measurement (lying and standing) to assess for mineralocorticoid replacement adequacy NICE NG243.
- Electrolyte testing to monitor for imbalances related to mineralocorticoid therapy NICE NG243.
- HbA1c testing to monitor for glucose metabolism disturbances NICE NG243.
- Bone density assessment at least once in the 5 years after diagnosis for adults, especially if risk factors are present NICE NG243.
- Lipid profile testing for adults to evaluate cardiovascular risk NICE NG243.
- Regular clinical review of signs and symptoms of under- or over-replacement, including weight changes, fatigue, hyperpigmentation, skin thinning, and metabolic disturbances NICE NG243.
- In children and young people, monitoring height, weight, pubertal development, bone age, and signs of low blood glucose, with additional assessments like bone density if growth has ceased or fractures occur NICE NG243.